Key points
- Net revenue US$115M in FY2026, first full year post launch
- Highly profitable single product on stand-alone basis
- Phase 3 Pipeline with Multiple Blockbuster Opportunities
Full summary
Mesoblast Ltd has successfully launched Ryoncil in the US, generating US$115M in net revenue in FY2026. The company has achieved profitability and reinvested proceeds into its Phase 3 programs. The company's pipeline includes multiple blockbuster opportunities such as Rexlemestrocel-L for chronic low back pain and inflammatory heart failure. Mesoblast also plans to extend Ryoncil's label to adult aGvHD and pediatric rare diseases. The company has a strong intellectual property portfolio and a dominant market leadership position.
Guidance
Net revenue US$115M in FY2026, first full year post launch
Outlook
Mesoblast plans to extend Ryoncil's label to adult aGvHD and pediatric rare diseases. The company also plans to complete BLA filing for Rexlemestrocel-L for chronic low back pain and chronic heart failure.